Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease

Eid, Ryan; Wudneh, Eden; Zahid, Soombal; Cahill, Katherine N.; Jerschow, Elina

doi:10.1016/j.anai.2019.09.023

Cited by 5 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it was limited by sample size, SNOT22 values between atopic and non atopic patients did not show any differences at statistical analysis. These data are surely interesting and are in line with previous reports, that demonstrated the efficacy of omalizumab in reducing symptomatic burden of CRSwNP, regardless the atopic status of patients [14,15]. On this topic, two phase III RCTs (POLYP 1 and 2), evaluating the efficacy of omalizumab on CRSwNP regardless diagnosis of asthma or atopic status, have been recently completed and results will shortly be published (NCT03280550 and NCT03280537).…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad

Cameli

d’Alessandro

Bergantini

et al. 2020

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Omalizumab proved to be very effective in improving control of severe atopic asthma. Many small-sized studies suggested a potential role for omalizumab in the management of aspirin-exacerbated respiratory disease. The aim of this study is to describe the effectiveness of omalizumab in a multicentre group of patients with Samter’s triad. We retrospectively enrolled eight patients (5 females) with Samter’s triad who underwent at least one year of omalizumab therapy. Clinical data, functional parameters and questionnaires for asthma and nasal polyposis control were collected at baseline and follow-up. We observed a significant reduction of moderate-to-severe asthma exacerbations, together with an increase of FEV1 and a reduction of steroids intake. An improvement in asthma control and nasal symptoms was also reported. This multicenter study confirms the effectiveness of omalizumab in patients affected by Samter’s triad. Omalizumab may represent a potential therapeutic option for the management of this disease.

show abstract

Section: Discussionsupporting

confidence: 81%

“…Unfortunately, few data is available on the efficacy of other biological therapies on Samter's triad; conflicting results have been published on mepolizumab efficacy, while dupilumab showed promising results on sinus symptoms [6,15,16].…”

Section: Discussionmentioning

confidence: 99%

A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad

Cameli

d’Alessandro

Bergantini

et al. 2020

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

show abstract

“…In a small case series examining 4 patients with AERD who had severe corticosteroid-dependent asthma, treatment with mepolizumab was associated with poor asthma control albeit the authors did not evaluate sinonasal symptoms in these same patients. 36 It is thus possible that targeting eosinophils may provide differential effects in the nose and lung, might not be effective in all patients with AERD, and that disease heterogeneity may exist among the population.…”

Section: Targeting Eosinophils In Aerdmentioning

confidence: 99%

Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease

Eid

Yan

Stevens

et al. 2021

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…These changes are likely due to the direct inhibition of IL-5α-receptor signaling on eosinophils, basophils, mast cells, and epithelial cells [66 ▪▪ ]. Nevertheless, not all AERD patients benefit from mepolizumab and some experience recurrence of the symptoms and break-through eosinophilia despite their compliance with therapy [67 ▪ ]. Notably, AERD patients with the lack of therapeutic benefit to mepolizumab had high baseline eosinophil or IgE levels [67 ▪ ,68 ▪ ].…”

Section: Mepolizumabmentioning

confidence: 99%

New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease

Sehanobish

Asad

Jerschow

2021

Current Opinion in Allergy &Amp; Clinical Immunology

Self Cite

View full text Add to dashboard Cite

Purpose of reviewThe purpose of this review is to provide a comprehensive summary of the current understanding of the pathogenesis of aspirin-exacerbated respiratory disease (AERD), and an update on its management. Recent findingsElevated levels of 15-oxo-eicosatetraenoic acid (15-Oxo-ETE), a newly described metabolite of arachidonic acid, have been identified in nasal polyps of AERD patients. In nasal polyps, activated basophils, and interleukin-5 -receptor-a-positive IL-5Ra þ plasma cells are associated with more severe nasal polyposis in AERD. Alveolar monocyte-derived macrophages and their persistent proinflammatory activation were suggested as putative factors contributing to AERD. Although not AERD-specific, three biological agents are now available for the management of both nasal polyposis and asthma. SummaryA newly downstream product of 15-lipoxygenase, 15-Oxo-ETE, was recently found to be significantly elevated in nasal polyps from AERD patients. This eicosanoid metabolite likely originates from an interplay between epithelial cells and mast cells. Nasal polyp basophils, IL-5Ra þ plasma cells, and alveolar macrophages were identified as important contributors to inflammation in AERD. Besides traditional aspirin desensitization and treatment for AERD management, several biologics for treatment of asthma are available, including three that have been approved for nasal polyposis. These biologic agents show variable rates of success in controlling AERD symptoms.

show abstract

Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease

Cited by 5 publications

References 11 publications

A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad

A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad

Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease

New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease

Contact Info

Product

Resources

About